HEAD-TO-HEAD STUDY SHOWS ORAL FERRIC MALTOL (FERACCRU®) MAY BE AN ALTERNATIVE TREATMENT TO INTRAVENOUS (IV) FERRIC IRON, OFFERING A REAL ALTERNATIVE OPTION TO HOSPITAL ADMINISTRATION FOR PATIENTS WITH IRON DEFICIENCY ANAEMIA (IDA) AND INACTIVE INFLAMMATORY BOWEL DISEASE (IBD)
22 October 2019
Please see below a list of all patient organisations to which Norgine provided financial support and/or significant indirect/non-financial support or engaged for contracted services. Included in this list are staff fund raising events and donations as well as descriptions of the nature of the support/contracted services which should enable the reader to understand the significance of the support that the patient organisation received, as well as the monetary value of the support.
In line with the EFPIA Code of Practice and various country Disclosure Codes and legal requirements for transparency, Norgine is disclosing its interactions and relevant transfers of value with healthcare professionals and healthcare organisations. This information includes the support to healthcare organisations in the form of donations and grants, as well as benefits in kind and sponsorship agreements to manage an event. It also covers the support to healthcare professionals with contributions to cost of events, including registration fees, travel and accommodation, as well as service and consultancy fees and related expenses that may arise. Finally, transfers of value associated with Research and Development are provided.
Please click on the relevant country icon to view the information related to medicinal products:
If a flag for a particular European country is not displayed above, Norgine does not have interactions or transfers of value data to report for that country. Please also note that Norgine works with third parties in some countries and it is the responsibility of the third party to report any qualifying interactions publicly.